Is compounded tirzepatide still legal in 2026?

What is already illegal, and since when

The tirzepatide shortage began in December 2022. During a declared shortage, licensed pharmacies can legally compound drugs that are "essentially a copy" of the scarce branded product. That is what thousands of 503A and 503B pharmacies did for roughly two years, producing compounded tirzepatide at prices well below Zepbound's list price. For background on how that compounding infrastructure works, see how compounding pharmacies are regulated.

On March 19, 2025, the FDA resolved the tirzepatide shortage. The exemption expired that day. 503B outsourcing facilities lost all legal authority to bulk-compound tirzepatide from that date forward, shortage or no shortage, because tirzepatide did not appear on the 503B Bulks List. The Outsourcing Facilities Association went to court. Judges denied preliminary injunctions. The 503B door was already closed before the FDA proposed anything new.

What the April 30, 2026 proposal actually does

The FDA's April 30 proposal to exclude semaglutide, tirzepatide, and liraglutide from the 503B Bulks List is not the first action. It is the final lock on a door that is already shut. The proposed rule would codify the exclusion formally, which means it would apply even if these drugs were declared scarce again in the future. Without the formal exclusion, a new shortage declaration could reopen the 503B window. With it, that pathway is gone permanently.

The FDA found no clinical need for outsourcing facility compounding of these drugs. Its reasoning: Zepbound, Mounjaro, Wegovy, and Ozempic are available in multiple doses and formulations. The commercial supply is stable. Adverse event reports tied to compounded versions numbered 455 for semaglutide and 320 for tirzepatide as of early 2025, many involving dosing errors from multi-dose vials that patients drew up themselves. The agency concluded the risk outweighs any access benefit a 503B framework would provide.

The 503A window: still open, but narrow

A 503B outsourcing facility fills large batches, not individual prescriptions. A 503A pharmacy fills a specific prescription for a specific patient, under a prescriber's supervision and a state pharmacy board's oversight. The 503A framework is not governed by the 503B Bulks List. So the 503B exclusion proposal does not directly touch 503A.

What does govern 503A compounding of an FDA-approved drug? The "essentially a copy" prohibition. A 503A pharmacy cannot compound a product that is essentially the same as a commercially available drug unless there is documented clinical need. Cost savings alone is not clinical need. Convenience is not clinical need.

What does qualify? An allergy to a specific inactive ingredient in Zepbound or Mounjaro that cannot be addressed by the commercially available formulation. An atypical dose not available in commercial form, documented by the prescriber. A patient who cannot use the auto-injector pen for a specific physical reason, and requires a different delivery format. These situations exist. They are not common. Prescribers need to document the specific reason in writing, and pharmacies need to verify the clinical justification exists before compounding.

If you are obtaining compounded tirzepatide from a 503A pharmacy, the legitimate question to ask your prescriber is: what is the documented clinical reason in my record? If the answer is "it costs less" or "my provider just recommends it," that is not a legally adequate justification under current FDA enforcement policy.

Why the adverse event data matters here

The FDA's safety concerns are not abstract. The most common problem with compounded tirzepatide was not contamination. It was dosing error. Compounded versions typically arrived in multi-dose vials, and patients drew up their own doses with syringes. Tirzepatide doses range from 2.5mg to 15mg across the titration schedule. A 10% measurement error on a 5mg dose is 0.5mg. At higher doses, errors can be larger.

Branded Zepbound uses single-dose auto-injector pens with fixed doses. There is no calculation step, no syringe, no vial. The difference in dosing precision between the two delivery systems is real, and it appears in the adverse event data.

What to do if you were using compounded tirzepatide

Talk to your prescriber about switching to Zepbound. Zepbound starts at $299 per month through LillyDirect for patients without insurance coverage. Medicare Part D patients can access it for $50 per month starting July 1, 2026. Savings card programs are available for eligible commercially insured patients. For a current breakdown of what tirzepatide costs through official channels, see the tirzepatide cost comparison. For a full comparison of what GLP-1 programs are available right now, see the best GLP-1 programs.

If you have a genuine documented medical reason for compounded tirzepatide, such as an allergy to a Zepbound inactive ingredient, that conversation needs to happen between you and your prescriber, with the clinical justification in writing and a licensed 503A pharmacy filling the script. That narrow path is still open. Everything else is not.

For a fuller look at the compounding landscape across both semaglutide and tirzepatide, including the price war, the B-vitamin modification workaround for semaglutide, and which telehealth providers are still operating legitimately, see compounded GLP-1s in 2026. For what tirzepatide actually costs through official channels today, see the tirzepatide cost comparison.

What happens after the comment period closes

The FDA reviews public comments and issues a final rule. That process typically takes months. During the interim, the current legal framework applies: 503B is closed, 503A requires documented clinical justification.

If the rule is finalized as proposed, future shortage declarations would not reopen the 503B pathway for tirzepatide, semaglutide, or liraglutide. The practical effect for most patients is zero change from today. The legal effect is a permanent rather than a contingent exclusion.

For the compounding industry, the stakes are higher. 503B outsourcing facilities like Empower Pharmacy and Strive Pharmacy built significant GLP-1 businesses during the shortage years. A permanent exclusion closes that future avenue. The larger fight for these facilities is now on the 503A side, in courts and in state pharmacy boards.

The bottom line on tirzepatide legality in 2026

Most of the legal question was settled 15 months ago. 503B compounding ended March 2025. The April 2026 FDA proposal adds a formal, permanent exclusion that would survive future shortage declarations. A 503A window remains for documented medical need, and it is narrow.

The cleaner path for most people: switch to Zepbound. The price is not what it was in 2023. The dose accuracy and quality controls are better. And the legal exposure on compounded tirzepatide without documented clinical justification is real, not theoretical, under current enforcement policy.